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Hemorrhagic cystitis (HC) can be a severe complication in hematopoietic stem cell transplantation (HSCT). To
identify risk factors and etiology and to improve treatment, a number of factors were analyzed retrospectively
in a cohort of 74 consecutive pediatric HSCTs between 2007 and 2009 in a single institution. The 74
transplantations were done in 67 children. Potential risk factors for HC were age, gender, underlying disease,
ablative conditioning, graft-versus-host disease prophylaxis, unrelated donor, stem cell source, conditioning
regime, acute graft-versus-host disease and cytomegalovirus reactivation.
Fourteen patients developed HC (19%). In all but 4 cases (71%), HC appeared after engraftment. Severity was
assessed as grade 1 in 1, grade 2 in 8, and grade 3 in 5 cases. In 79% of the patients with HC, urine samples
showed BK virus. This may provide guidance for future prevention policies. In 11 children, treatment included
forced hydration, spasmolytics, and bladder irrigation. Three children required cystoscopy, intravesical
therapy and/or antiviral therapy. Statistical analysis revealed age over six years to be a risk factor for the
development of HC.
We conclude that current conditioning regimens lead to a still considerable incidence of HC in pediatric
HSCT, necessitating the evaluation of screening protocols and preventive measures.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION Deﬁnitions
The symptoms of HC are classiﬁed as follows: grade 1 shows micro-Hemorrhagic cystitis (HC) has been reported to be
a frequent complication of allogeneic hematopoietic stemcell
transplantation in children. In the literature, the incidence is
found to vary among different studies between 10% and 70%.
This partly depends on the deﬁnitions and classiﬁcation used
[1]. Symptoms vary from microscopic to macroscopic
hematuria with clots, urinary obstruction, and renal and/or
bladder damage. Early-onset HC, occurring before engraft-
ment, is seen as a complication of the conditioning regimen
with cyclophosphamide, busulfan and/or etoposide as
potential risk factors [1-3]. There is still an ongoing debate
about total body irradiation as a risk factor for HC [4-6]. Late-
onset HC is associatedmainly with BK virus as well as with JC
virus, adenovirus, and cytomegalovirus (CMV) virus [3,7-9].
In this study, the inﬂuence of donor, recipient, and
transplantation-speciﬁc variables on hemorrhagic cystitis in
a cohort of pediatric transplantations was analyzed.PATIENTS AND METHODS
Patients
All children in our center who underwent an allogeneic stem cell trans-
plantationbetween2007 and2009were included in this retrospective analysis.
All patients gave informed consent to analyze their clinical data. The informed
consent procedure was approved by the ethics committee of the hospital.
The charts of these children were reviewed to identify the characteris-
tics deﬁned in Table 1.dgments on page 1266.
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13.05.014scopic hematuria; grade 2, macroscopic hematuria; grade 3, macroscopic
hematuria with clots, and grade 4, macroscopic hematuria with clots,
urinary obstruction, kidney damage, and bladder damage [1-3,7].
There was no screening on microscopic hematuria; all patients showing
symptoms were evaluated. Hemorrhagic cystitis was deﬁned as microscopic
or macroscopic hematuria and dysuria with a negative bacterial culture in
the urine and no other hemorrhagic conditions [2]. A patient was considered
recovered when complaints disappeared; urine samples were no longer
monitored for hematuria. PCR was applied to diagnose possible viruria
and/or viremia with BK, adeno and JC viruses.
Engraftment was deﬁned as neutrophil count over .5  109/L for three
consecutive days [9,10]. Graft-versus-host disease (GvHD) classiﬁcation was
according to Glucksberg, and GvHD > grade 1 was evaluated as a potential
risk factor.Statistical Methods
To determine the risk factors for the occurrence of HC, we used a Cox
regression analysis for the constant variables; for the transplantation-
related factors a logistic regression was used. In this analysis the hazard
ratio and the P value were calculated.When the P valuewas less than .01, the
variable was considered signiﬁcant.
The constant variables were age, gender, underlying disease, Fanconi
adapted conditioning versus ablative conditioning, GvHD prophylaxis,
serotherapy, related/unrelated donor, stem cell source and conditioning
regime [2,8,9,11,12]. The median age was 6 years. This variable was grouped
as 0 to 6 years and > 6 years. The stem cell sources peripheral blood stem
cells (PBSC) and bone marrow (BM) were combined as PBSC was only used
in three cases. The transplantation-related factors were acute GvHD
(> grade 1) and a reactivation of CMV (> 1000 copies) [2,9,11].
Statistical Analysis
Data were analyzed in SPSS 15.0.RESULTS
Patient and Treatment Characteristics
Sixty-seven children were included in this study. Of
those, ﬁve children underwent transplantation twice, and
Table 1
Characteristics and Univariate analysis for Hemorrhagic Cystitis
Variables HC
n ¼ 14
No HC
n ¼ 60
Total
n ¼ 74
Hazard ratio 95% CI P Value
Age, yr
0 to 6 3 37 40
> 6 11 23 34 4.748 1.324 to 17.025 .017
Gender
Male 10 38 48 1.427 .448 to 4.551 .548
Female 4 22 26
Underlying disease
Malignant 10 40 50 1.190 .448 to 4.551 .769
Nonmalignant 4 20 24
Conditioning
Ablative 13 53 66 1.717 .225 to 13.130 .602
Nonablative 1 7 8
GvHD prophylaxis
CsA 1 30 31
CsA and MTX 5 18 23 .111 .007 to 1.791 .121
CsA and prednisone 7 11 18 .283 .042 to 3.103 .353
Other* 1 1 2 .360 .033 to 2.436 .250
Serotherapy
Yes 12 44 56 2.169 .485 to 9.697 .311
No 2 16 18
Donor
Related 2 17 19
Unrelated 12 43 55 2.353 .526 to 10.521 .263
CMV reactivationy
Yes 3 7 10 2.429 .528 to 11.181 .225
No 11 53 64
Stem cell source
Bone marrow þ
PBSCT 7 30 37 1.173 .0684 to 2.012 .562
Cord blood 7 30 37
Conditioning regimen
Cy þ Bu (Mel) 5 (0) 16(3) 21 (3)
TBI þ VP-16 3 13 16
Bu þ Flu 1 11 12
Cy þ Flu 0 5
Otherz 5 12 17
aGvHDx
Yes 1 13 14 .348 .041 to 2.972 .335
No 13 47 60
CsA indicates cyclosporine; HC, hemorrhagic cystitis; PBSCT, peripheral blood stem cell transplantation; Cy, cyclophosphamide; Bu, busulfan; CMV, cytomeg-
alovirus; TBI, total body irradiation; MTX, methotrexate; Eto, etoposide; Flu, ﬂudarabine; Mel, melphalan; aGvHD, acute graft-versus-host disease.
* includes methotrexate or tacrolimus and prednisone.
y CMV reactivation deﬁned as viral load > 1000 copies.
z includes CyþBuþVP-16 or Fluþtreosulfan or TBIþVP16þthiotepa or CyþBuþFlu or TBI or Fluþthiotepa or FluþMelþtreosulfan or treosulfan or Flu or
CyþTBIþthiotepa.
x indicates GvHD > grade 1.
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in 74 transplantations. Four children died before day 56 after
transplantation [9].
All patients who received cyclophosphamide were
prophylactically treated with Mesna (2-Mercaptoethane
sulfonate sodium)[13] in a daily dose equal to the
cyclophosphamide dose, divided in 6 doses, up to 24 hours
past the last cyclophosphamide dose, according to the
institutional protocol.
Hyperhydration was also according to institutional
protocol with 3 L/m2/day.
Seven patients with Fanconi anemia had conditioning
regimens, adapted to the underlying condition.
According to institutional protocols, IgG levels were
checked regularly and i.v. IgG was supplemented in case
levels fell below 4 g/L.
Treatment of hemorrhagic cystitis was according to local
standard operating procedures, depending on severity
[1-3,7]. Treatment consisted of conservative measures, such
as forced hydration, spasmolytics, and analgesics. In severe
cases (grades 2 and 3 HC), complimentary options were used,such as optimization of the hematological homeostasis,
bladder irrigation, cystoscopy, intravesical therapy with
pentosanpolysulphate, heparin, granulocyte-macrophage
colony stimulating factor (GM-CSF) and intravenous cidofo-
vir [1,7,14,15].
Incidence of Hemorrhagic Cystitis
The incidence of hemorrhagic cystitis was 19% (14 of 74
patients). In total, four patients died before 56 days after
transplantation [9]. Two of those patients developed HC.
One patient had grade 2 HC and died 22 days after
transplantation of respiratory insufﬁciency and multiple
infections during aplasia. There was no recovery from HC.
The other patient died 52 days after transplantation of
progressive neurological complications, having recovered
from HC grade 3.
The median time to HC was 27 days (range, 0 to 76 days)
after stem cell transplantation and persisted for a median of
38 days (range, 6 to 18 days). Neutrophil engraftment
occurred after a median time of 24 days (range, 15 to
74 days). One patient showed HC symptoms two days before
Figure 1. Cumulative incidence curve.
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occurred after 74 days and, therefore, the hemorrhagic
cystitis was formally pre-engraftment (24 days after
transplantation).
There was one patient with grade 1 HC, 8 patients with
grade 2 HC, and ﬁve patients with grade 3 HC; there were
no patients with grade 4 HC. The HC in the patient with grade
1 HC appeared seven days postengraftment and persisted for
six days. In the eight patients with grade 2 HC, the hemor-
rhagic cystitis occurred on amedian of 25 days after stem cell
transplantation and 15 days postengraftment (range, 6 to
54 days). The HC had a median duration of 20 days (range, 6
to 57 days). HC appeared in the ﬁve patients with grade 3 HC
on a median of 13 days post-SCT and -17 days postengraft-
ment (range, -50 to 4 days). The HC persisted for a median of
76 days (range, 12 to 118).
Risk Factor Analyses
Table 1 shows the potential predictors of HC evaluated.
The majority of the patients (71%) had a malignant under-
lying disease. Of the patients with HC, 79% were older than
six years, 71% were male, and 86% received serotherapy in
the conditioning. Acute GvHD (hazard ratio [HR], .348; 95%
conﬁdence interval [CI], .041 to 2.972; P ¼ .335) and CMV-
reactivation (HR, 2.429; 95% CI, .528 to 11.181; P ¼.225)
were not signiﬁcant related with HC. In multivariate analysis,
an age of more than 6 years showed a signiﬁcant association
(P ¼.017, Table 1). The survival in the patients with HC was
71%; in the patients without HC, survival was 78% (not
signiﬁcant). The cause of death in none of the patients was
directly related to HC.
Micriobiological Studies
In 10 of the 14 patients affected, HC appeared post-
engraftment. Thus, it does not seem to be related to
conditioning regimens and was associated with viruses
detected in the urine using PCR. Of the 4 patients who
developed HC pre-engraftment, the relation between early
manifestations of HC and conditioning regimen chemo-
therapy is uncertain because the urine samples of three of
these patients showed a positive PCR of BK virus as well.
Overall, in 79% BK virus was found; in one case JC virus was
diagnosed (grade 1 HC) and in two patients no cause could be
identiﬁed (grades 2 and 3).
The viral load of BK virus in urine varied between 4.1107
copies and 6.4  108 in grade 2 HC and between 2.2  108
copies and 7.2 108 in grade 3 HC. Therewas no screening of
BK-viremia in healthy patients.
Therapy
The patient with grade 1 HC was treated with forced
hydration, spasmolytics, and analgesics.
Of the 8 patients with grade 2 HC, in 4 the thrombocyte
count was optimized with thrombocyte transfusion and
the thrombocyte levels were maintained above 20  109 or
50  109, depending on severity. In one of those patients,
supportive care was added as described above for grade 1.
Two of the grade 2 patients were treated with conservative
measures and one was not treated at all. In this patient the
HC persisted 14 days. The patient who died 22 days after
undergoing transplantation was treated with thrombocyte
transfusions.
In all of the 5 patients with grade 3 HC, the treatment
consisted of conservative therapy and thrombocyte trans-
fusions, according to standard local procedures. Three ofthose received one or more bladder irrigations with normal
saline and one of them had a cystoscopy to remove clots. This
patient was also treated with GM-CSF intravesically
(according to Vela-Ojeda et al. [14]) and received cidofovir
intravenously because of an adenovirus infection. Apart from
undergoing bladder irrigation, one patient was treated
intravesically with pentosanpolysulphate, heparin, and
GM-CSF. This patient was also intravenously treated with
cidofovir. In this case, cidofovir was prescribed speciﬁc for
the BK cystitis.
Cumulative Incidence Curve
For the cumulative incidence curve, see Figure 1.
DISCUSSION
We analyzed incidence, etiology, risk factors, diagnostics,
and therapy of HC as a complication of allogeneic stem cell
transplantation in children. In this study the incidence of
clinical signs of hemorrhagic cystitis was 19%, which is rather
low compared to the incidence of HC as described in the
literature [1]. Age over six years was associated with an
increased risk in a multivariate analysis.
This cohort was not screened for HC. This may have
contributed to the low incidence of hemorrhagic cystitis.
Early HC is uncommon in our series, which may indicate
efﬁcient prophylaxis of conditioning regimen-induced HC. In
our center, the most striking recent developments are the
replacement of cyclophosphamide by ﬂudarabin as well as
the use of tailored intravenous busulfan (area under the
curve targeted). The main cause of HC was, therefore,
deemed to be viral.
The fact that 79% of HCwas caused by the BK virus implies
that this could play a signiﬁcant role in the future, aiming at
prevention and treatment of HC. In a prospective study by
Cesaro et al. [9], 87.5% of the patients with HC had a positive
urine test PCR for BK virus and BK virus was present in the
blood in 75% of the cases. It seems warranted to set up
a prospective study to evaluate screening on BK virus in the
urine and pre-emptive treatment.
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was age > 6 years. Because we analyzed relatively small
patient numbers, higher numbers are needed to achieve
a more robust risk analysis.
In the literature, there is a fair consensus concerning
younger age to be a risk factor for developing HC. The cut-off
point varies from 7 to 10 years [7,16]. Younger age may
protect against HC as younger patients may have been
exposed less often to BK virus. This hypothesis deserves
further research.
In our center, there was a standard procedure to treat
a patient diagnosed with HC initially; the ﬁrst steps of the
therapy (conservative therapy and optimization of the
hematological homeostasis) were clearly deﬁned. If this
treatment turned out to be insufﬁcient, there was no further
uniform protocol. In our retrospective study, it was merely
with conservative therapy that patients were treated
successfully. Decker et al. [1] show steps that can possibly be
taken to reduce the duration if there is progression to grades
3 or 4 HC. In this review, the ﬁrst steps to treat patients with
HC are forced hydration, spasmolytics, analgesics, and
normal saline continuous bladder irrigation. Cystoscopywith
clot evaluation is recommended when HC persists over 3 to
4 days. Patients should be treated with intravesical therapy,
including aluminium potassium sulfate, cidofovir, or pros-
taglandins when HC persists over another 3 to 4 days. Decker
et al. recommended the following next steps when HC
persists over another 7 to 10 days: First, patients should
be treated with intravenous or oral with pentosanpoly-
phosphate or estrogen. Patients can be treated with
hyperbaric oxygen therapy, as well. Second, ﬁbrin sealant
therapy should be considered. Finally, surgical options, such
as bilateral percutaneous nephrostomy tubes, with or
without ureteral occlusion, selective arterial embolization, or
cystectomy, should be considered [1].
Haines et al. [12] showed that there is a relation between
a high plasma BK viral load and both the severity of HC and of
renal failure. In our study, the viral load of BK in urine does
not show a relation with the severity of HC. The viral load in
the urine was not higher in the patients with grade 2 or 3 HC.
We, however, did not measure plasma loads of BK; this may
be of interest for future research. Our ﬁnding of low urine
viral loads may imply that effective prophylaxis of
BK-induced HC may prove difﬁcult. The most promising
approach for the future seems to be early intervention,
guided by urine screening and pre-emptive treatment while
urine viral loads are still low.
In general, it may be possible to decrease the incidence of
HC by aiming at earlier immune recovery by adoptive cellular
therapies and/or decreased doses of serotherapy. Thesefuture developments will have an important impact on
hospitalization rates, costs and quality of life.
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